Diabetic Neuropathy: Pathogenesis and Treatment. A Review

Neuropathy is a common and devastating complication of diabetes that contributes to mortality in most cases. Multiple factors are thought to play a major role in the pathogenesis of diabetic neuropathy, including alterations in the endoneural metabolism, defective neurotrophic factors, reduced nerve blood supply, and immune mechanisms. Studies of endoneural metabolism and nerve blood-flow alterations have focused on oxidative stress, the polyol pathway, advanced glycation, protein kinase C, and impaired essential fatty acid metabolism. Although many experimental and clinical studies have been performed to determine the most optimal strategy for preventing and treating diabetic neuropathy, tight glycemic control is the mainstay of therapy. In this article, the proposed pathophysiologic mechanisms and therapeutic approaches in diabetic neuropathy are reviewed and discussed with the relevant literature.

KEYWORDS

Diabetic neuropathy - pathogenesis - treatment - decompression

REFERENCES

• 1 Sima A A, Thomas P K, Ishii D, Vinik A. Diabetic neuropathies.  Diabetologia. 1997;  40 B74-B77
• 2 Greene D A, Stevens M J, Feldman E L. Diabetic neuropathy: scope of syndrome.  Am J Med. 1999;  107 2S-8S
• 3 The DCCT Research Group . Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetes control and complications trial.  Diabetes. 1988;  37 476-481
• 4 Sangiorgio L, Iemmolo R, Le Moli R et al.. Diabetic neuropathy: prevalence, concordance between clinical and electrophysiological testing and impact of risk factors.  Panminerva Med. 1997;  39 1-5
• 5 Fedele D, Comi G, Coscelli C et al.. A multicentre study on the prevalence of diabetic neuropathy in Italy: Italian diabetic neuropathy group.  Diabetes Care. 1997;  20 836-843
• 6 Vaillancourt P D, Langevin H M. Painful peripheral neuropathies.  Med Clin North Am. 1999;  83 627-642
• 7 Thomas P K. Classification, differential diagnosis and staging of diabetic peripheral neuropathy.  Diabetes. 1997;  46(suppl 2) S54-S57
• 8 Anand P, Terenghi G, Warner G et al.. The role of endogenous nerve growth factor in human diabetic neuropathy.  Nat Med. 1996;  2 703-707
• 9 Cameron N E, Eaton S E, Cotter M A, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.  Diabetologia. 2001;  44 1973-1988
• 10 Diabetes Control and Complication Trial (DCCT) Research Group . The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus.  N Eng J Med. 1993;  329 977-986
• 11 Vinik A I. Diabetic neuropathy: pathogenesis and therapy.  Am J Med. 1999;  107 (2B) 17S-26S
• 12 Van Dam P S. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives.  Diabetes Met Res Rev. 2002;  18 176-184
• 13 Greene D A, Lattimer S A, Sima A A. Perspectives in diabetes: are disturbances of sorbitol phosphoinositide and Na⁺-K⁺-ATPase regulation involved in pathogenesis of diabetic neuropathy?.  Diabetes. 1988;  37 688-693
• 14 Cameron N E, Cotter M A. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.  Diabetes Res Clin Prac. 1999;  45 137-146
• 15 Ward K K, Low P A, Schmelzer J D, Zochodne D W. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats.  Brain. 1989;  112 197-208
• 16 Low P A, Nickander K K, Tritschler H J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy.  Diabetes. 1997;  46(suppl. 2) S38-S42
• 17 Wolff S P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications.  Br Med Bull. 1993;  49 642-652
• 18 Blakytyn R, Harding J J. Glycation (non-enzymatic glycosylation) inactivates glutathion reductase.  Biochem J. 1992;  288 303-307
• 19 Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications.  Nutrition. 2001;  17 888-895
• 20 Lindner V, Collins T. Expression of NF-kappa B and I kappa B-alpha by aortic endothelium in an arterial injury model.  Am J Pathol. 1996;  148 427-438
• 21 Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals.  J Membr Biol. 1986;  89 1-8
• 22 Takagi Y, Kashiwagi A, Tanaka Y et al.. Significance of fructose-induced protein oxidation and formation of advanced glycation end product.  J Diabetes Complications. 1995;  9 87-91
• 23 Greene D A, Lattimer S A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation.  J Clin Invest. 1983;  72 1058-1063
• 24 Yorek M A, Dunlap J A, Stefani M R. Restoration of Na⁺-K⁺ pump activity and resting membrane potential by myo-inositol supplementation in neuroblastoma cells chronically exposed to glucose or galactose.  Diabetes. 1991;  40 240-248
• 25 Cameron N E, Cotter M A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy.  Diabetes. 1997;  46(suppl 2) S31-S37
• 26 Pop-Busui R, Marinescu V, Van Huysen C et al.. Dissection of metabolic, vascular and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.  Diabetes. 2002;  51 2619-2628
• 27 Yasuda H, Dyck P J. Abnormalities of endoneural microvessels and sural nerve pathology in diabetic neuropathy.  Neurology. 1987;  37 20-28
• 28 Giannini C, Dyck P J. Ultrastructural morphometric abnormalities of sural nerve endoneural microvessels in diabetes mellitus.  Ann Neurol. 1994;  36 408-415
• 29 Tesfaye S, Malik R, Ward J D. Vascular factors in diabetic neuropathy.  Diabetologia. 1994;  37 847-854
• 30 Tuck R R, Schmelzer J D, Low P A. Endoneural blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy.  Brain. 1984;  107 935-950
• 31 Stevens E J, Carrington A L, Tomlinson D R. Nerve ischemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models.  Diabetologia. 1994;  37 43-48
• 32 Tesfaye S, Harris N, Jakubowski J J et al.. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography.  Diabetologia. 1993;  36 1266-1274
• 33 Young M J, Veves A, Walker M G, Boulton A J. Correlation between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy?.  Diabetologia. 1992;  35 1146-1150
• 34 Kilo S, Berghoff M, Hilz M, Freeman R. Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy.  Neurology. 2002;  54 1246-1252
• 35 Kihara M, Low P A. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy.  Exp Neurol. 1995;  132 180-185
• 36 Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.  J Clin Invest. 1991;  87 432-438
• 37 Apfel S C. Neurotrophic factors in the therapy of diabetic neuropathy.  Am J Med. 1999;  107 (2B) 34S-42S
• 38 Hellweg R, Raivich G, Hartung H D et al.. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy.  Exp Neurol. 1994;  130 24-30
• 39 Brewster W J, Fernyhough P, Diemel L T et al.. Diabetic neuropathy, nerve growth factor and other neurotrophic factors.  Trends Neurosci. 1994;  17 321-325
• 40 Tomlinson D R, Fernyhough P, Diemel L T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors.  Diabetes. 1997;  46(Suppl) S43-S49
• 41 Wuarin L, Guertin D M, Ishii D N. Early reduction in insulin-like growth factor gene expression in diabetic nerve.  Exp Neurol. 1994;  130 106-114
• 42 Tan K, Baxter R C. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age.  J Clin Endocrinol Metab. 1986;  63 651-655
• 43 Hafer-Macko C E, Ivey F M, Gyure K A et al.. Thrombomodulin deficiency in human diabetic nerve microvasculature.  Diabetes. 2002;  51 1957-1963
• 44 Esposito C, Gerlach H, Brett J et al.. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.  J Exp Med. 1989;  170 1387-1407
• 45 Ferreira L D, Huey P U, Pilford B E et al.. Sciatic nerve lipoprotein lipase is reduced in streptozotocin-induced diabetes and corrected by insulin.  Endocrinology. 2002;  143 1213-1217
• 46 Huey P U, Marcell T, Owens G C et al.. Lipoprotein lipase is expressed in cultured Schwann cells and functions in lipid synthesis and utilization.  J Lipid Res. 1998;  39 2135-2142
• 47 Sharma K R, Cross J, Ayyar D R et al.. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy.  Arch Neurol. 2002;  59 751-757
• 48 Said G, Goulon Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy.  Ann Neurol. 1994;  35 559-569
• 49 Cocito D, Ciaramitaro P, Isoardo G et al.. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.  J Neurol. 2002;  249 719-722
• 50 Krendel D A, Zacharias A, Younger D S. Autoimmune diabetic neuropathy.  Neurol Clin. 1997;  15 959-971
• 51 Younger D S, Rosoklija G, Hays A P et al.. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies.  Muscle Nerve. 1996;  19 722-727
• 52 Kelkar P, Masood M, Parry G J. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy).  Neurology. 2000;  55 83-88
• 53 Vinik A I, Leichter S B, Pittenger G L et al.. Phospholipid and glutamic acid decarboxylase antibodies in diabetic polyneuropathy.  Diabetes Care. 1995;  18 1225-1232
• 54 Bravenboer B, Kappelle A C, Hamers F P et al.. Potential use of glutathion for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat.  Diabetologia. 1992;  35 813-817
• 55 Van Dam P S, Van Asbeck B S, Van Oirschot J F et al.. Glutathion and α lipoate in diabetic rats: nerve function, blood flow and oxidative state.  Eur J Clin Invest. 2001;  31 417-424
• 56 Ueno Y, Kizaki M, Nakagiri R et al.. Dietary glutathion protects rats from diabetic nephropathy and neuropathy.  J Nutr. 2002;  132 897-900
• 57 Wada H, Shintani D, Ohlrogge J. Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production.  Proc Natl Acad Sci USA. 1997;  94 1591-1596
• 58 Ou P, Tritschler H J, Wolff S P. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?.  Biochem Pharmacol. 1995;  50 123-126
• 59 Stevens M J, Obrosova I, Cao X et al.. Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy.  Diabetes. 2000;  49 1006-1015
• 60 Cameron N E, Cotter M A, Horrobin D H, Tritschler H J. Effects of α lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids.  Diabetologia. 1998;  41 390-399
• 61 Hounsom L, Horrobin D F, Tritschler H et al.. A lipoic acid-gamma linoleic acid conjugate is effective against multiple indices of experimental diabetic neuropathy.  Diabetologia. 1998;  41 839-843
• 62 Biessels G J, Smale S, Duis S E et al.. The effects of gamma-linoleic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats.  J Neurol Sci. 2001;  182 99-106
• 63 Ziegler D, Hanefeld M, Ruhnau K J et al.. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study).  Diabetologia. 1995;  38 1425-1433
• 64 Ziegler D, Schatz H, Conrad F et al.. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicentre trial (DEKAN Study).  Diabetes Care. 1997;  20 369-373
• 65 Ziegler D, Hanefeld M, Ruhnau K J et al.. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 7-month multicentre randomized controlled trial (ALADIN III Study). ALADIN III Study Group Alpha-Lipoic Acid in Diabetic Neuropathy.  Diabetes Care. 1999;  22 1296-1301
• 66 Kunt T, Forst T, Wilhelm A et al.. Alpha-lipoic acid reduces expression of vascular adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products.  Clin Sci (Lond). 1999;  96 75-82
• 67 Cotter M A, Love A, Watt M J et al.. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats.  Diabetologia. 1995;  38 1285-1294
• 68 Tütüncü N B, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study.  Diabetes Care. 1998;  21 1915-1918
• 69 Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes.  Am J Clin Nutr. 2001;  73 1052-1057
• 70 Cameron N E, Cotter M A. Neurovascular dysfunction in diabetic rats: potential contribution of autooxidation and free radicals examined using transition metal chelating agents.  J Clin Invest. 1995;  96 1159-1163
• 71 Keegan A, Cotter M A, Cameron N E. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats.  Free Radic Biol Med. 1999;  27 536-543
• 72 Cameron N E, Cotter M A. Effects of an extracellular metal chelator on neurovascular function in diabetic rats.  Diabetologia. 2001;  44 621-628
• 73 Pop-Busui R, Sullivan K A, Van Huysen C et al.. Depletion of taurine in experimental diabetic neuropathy: Implications for nerve metabolic, vascular and functional deficits.  Exp Neurol. 2001;  168 259-272
• 74 Obrosova I G, Fathallah L, Stevens M J. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy.  Exp Neurol. 2001;  172 211-219
• 75 Bril V. Status of current clinical trials in diabetic neuropathy.  Can J Neurol Sci. 2001;  28 191-198
• 76 Greene D A, Arezzo J C, Brown M B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.  Neurology. 1999;  53 580-591
• 77 Daniele E, Coco M P. Tolrestat in the therapy of diabetic peripheral neuropathy. Is this drug really useful?.  Clin Ther. 1995;  146 793-799
• 78 Obrosova I G, Van Huysen C, Fathallah L et al.. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism and oxidative defense.  FASEB J. 2002;  16 123-125
• 79 Handelsman D, Turtle J. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.  Diabetes. 1981;  30 459-464
• 80 Christensen J, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.  Acta Neurol Scand. 1985;  71 164-167
• 81 Uchida K, Kigoshi T, Nakano S et al.. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.  Clin Ther. 1995;  17 460-466
• 82 Asano T, Saito Y, Kawakami M, Yamada N. (Fidarestat Clinical Pharmacology Study Group) . Fidarestat (SNK-60), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.  J Diabetes Complications. 2002;  16 133-138
• 83 Cameron N E, Cotter M A, Dines K C et al.. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.  Diabetologia. 1997;  37 651-663
• 84 Koya D, King G L. Protein kinase C activation and the development of diabetic complications.  Diabetes. 1998;  47 859-866
• 85 Nakamura J, Kato K, Hamada Y et al.. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.  Diabetes. 1999;  48 2090-2095
• 86 Cotter M A, Jack A M, Cameron N E. Effects of protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes.  Clin Sci (Lond). 2002;  103 311-321
• 87 Keen H, Payan J, Allawi J et al.. Treatment of diabetic neuropathy with γ-linoleic acid.  Diabetes Care. 1993;  16 8-15
• 88 Cotter M A, Cameron N E. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats.  Prostaglandins Leukot Essent Fatty Acids. 1997;  56 337-343
• 89 Petty B G, Cornblath D R, Adornato B T et al.. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.  Ann Neurol. 1994;  36 244-246
• 90 Apfel S C, Kessler J A, Adornato B T et al.. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy.  Neurology. 1998;  51 695-702
• 91 Apfel S C, Schwartz S, Adornato B T et al.. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial.  JAMA. 2000;  284 2215-2221
• 92 Goss R J, Goins F W, Lacomis D et al.. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse.  Diabetes. 2002;  51 2227-2232
• 93 Apfel S C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right and what does the future hold ?.  Int Rev Neurobiol. 2002;  50 393-413
• 94 Zhuang H X, Snyder C K, Pu S F, Ishii D N. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats.  Exp Neurol. 1996;  140 198-205
• 95 Wang C, Li Y, Wible B et al.. Effects of insulin and insulin like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells.  Brain Res Mol Brain Res. 1992;  13 289-300
• 96 Calcutt N A, Campana W M, Eskeland N L et al.. Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats.  J Neuropathol Exp Neurol. 1999;  58 628-636
• 97 Krendel D A, Costigan D A, Hopkins L C. Successful treatment of neuropathies in patients with diabetic mellitus.  Arch Neurol. 1995;  52 1053-1061
• 98 Ogawa T, Taguchi T, Tanaka Y et al.. Intravenous immunoglobulin therapy for diabetic amyotrophy.  Intern Med. 2001;  40 349-52
• 99 Awada A, Dehoux E, al Jumah M, al Ayafi H. Rapidly evolving diabetic mononeuritis multiplex. Favorable outcome after immunosuppressive treatment.  Rev Neurol (Paris). 2001;  157 1427-1429
• 100 Yagihashi S, Kamijo M, Baba M et al.. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats.  Diabetes. 1992;  Jan;41 47-52
• 101 Cameron N E, Cotter M A, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats.  Diabetologia. 1992;  35 946-950
• 102 Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats.  Microvasc Res. 1997;  53 105-112
• 103 Wada R, Sugo M, Nakano M, Yagihashi S. Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na⁺,K⁺)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats.  Diabetologia. 1999;  42 743-747
• 104 Zhang W, Slusher B, Murakawa Y et al.. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.  J Neurol Science. 2002;  194 21-28
• 105 Butcher S P, Bullock R, Graham D I, McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion.  Stroke. 1990;  21 1727-1733
• 106 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen K F et al.. Effect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy: the Oslo study.  Br Med J. 1986;  293 1195-1199
• 107 Dahl-Jorgensen K. Near-normoglycemia and late diabetic complications: the Oslo study.  Acta Endocrinol. 1987;  115(suppl) 1-38
• 108 DCCT . The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).  Diabetologia. 1998;  41 416-423
• 109 Parry G J. Management of diabetic neuropathy.  Am J Med. 1999;  107 (2B) 27S-33S
• 110 Potter C G, Sharma A K, Farber M O, Peterson R G. Hypoglycemic neuropathy in experimental diabetes.  J Neurol Sci. 1988;  88 293-301
• 111 Ohshima J, Nukada H. Hypoglycemic neuropathy: microvascular changes due to recurrent hypoglycemic episodes in rat sciatic nerve.  Brain Res. 2002;  947 84-89
• 112 Orloff M J, Macedo A, Greenleaf G E. Effect of pancreas transplantation on diabetic somatic neuropathy.  Surgery. 1988;  104 437-444
• 113 Müller-Felber W, Landgraf L, Scheuer R et al.. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation.  Diabetes. 1993;  42 1482-1486
• 114 Martinenghi S, Comi G, Galardi G et al.. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycemic control provided by the pancreas.  Diabetologia. 1997;  40 1110-1112
• 115 Navarro X, Sutherland D E, Kennedy W R. Long-term effects of pancreas transplantation on diabetic neuropathy.  Ann Neurol. 1997;  42 727-736
• 116 Hopt U T, Drognitz O. Pancreas organ transplantation. Short and long-term results in terms of diabetes control.  Langenbeck's Arch Surg. 2000;  385 379-389
• 117 Landgraf R. Impact of pancreas transplantation on diabetic secondary complications and quality of life.  Diabetologia. 1996;  39 1415-1424
• 118 Vàrkonyi T T, Farkas G, Fülöp Z et al.. Beneficial effects of fetal islet grafting on development of late diabetic complications.  Transplant Proc. 1998;  30 330-331
• 119 Kale B, Yuksel F, Celikoz B et al.. Effect of various nerve decompression procedures on the functions of distal limbs in streptozotocin-induced diabetic rats: further optimism in diabetic neuropathy.  Plast Reconstr Surg. 2003;  111 2265-2272
• 120 Dellon A L. Treatment of symptomatic diabetic neuropathy by surgical decompression of multiple peripheral nerves.  Plast Reconstr Surg. 1992;  89 689-697
• 121 Dellon A L. Preventing foot ulceration and amputation by decompressing peripheral nerves in patients with diabetic neuropathy.  Ostomy Wound Management. 2002;  9 36-45
• 122 Aszmann O C, Kress K M, Dellon A M. Results of decompression of peripheral nerves in diabetics: a prospective, blinded study.  Plast Reconstr Surg. 2000;  106 816-822
• 123 Dellon A L, MacKinnon S E, Seiler W A. Susceptibility of the diabetic nerve to chronic compression.  Ann Plast Surg. 1988;  20 117-119
• 124 Dellon A L, Dellon E S, Seiler W A. Effect of tarsal tunnel decompression in streptozotocin-induced diabetic rats.  Microsurgery. 1994;  15 265-268
• 125 Tambwekar S R. Extended neurolysis of the posterior tibial nerve to improve sensation in diabetic feet.  Plast Reconstr Surg. 2001;  108 1452-3
• 126 Caffee H H. Treatment of diabetic neuropathy by decompression of the posterior tibial nerve.  Plast Reconstr Surg. 2000;  106 813-815